In this article, we will look at the 7 Most Undervalued Blue Chip Stocks to Invest In.Large-cap stocks have not exactly fallen out of favor, but the conversation around them has shifted. After a period where market leadership was concentrated in a narrow group of high-growth names, attention has started to broaden toward companies that combine scale with more reasonable valuations. That shift is partly driven by valuation fatigue at the top end, and partly by a growing focus on earnings durability. In that ...

Accenture plc (NYSE:ACN) is one of the best ethical companies to invest in now according to Reddit. TD Cowen cut the price target on Accenture plc (NYSE:ACN) to $275 from $282 on March 16, maintaining a Buy rating on the shares. The firm told investors that it updated its model ahead of the fiscal Q2 results, saying that, considering raised macro uncertainty and no clear end in sight with the Iran conflict, it believes that it is now reasonable that Accenture plc (NYSE:ACN) could just leave its FY26 growth ...

Core Viewpoint - EchoStar Corporation (NASDAQ:SATS) is highlighted as one of the 12 Most Shorted Stocks to Buy in 2026, with a price target increase from UBS analyst John Hodulik to $127 from $125 while maintaining a "Neutral" rating [1]. Financial Performance - The Q4 2025 results for EchoStar were mixed, showing an acceleration in Pay TV subscriber declines, although wireless losses improved due to a transition to an MVNO-focused strategy [2]. - For FY 2025, EchoStar reported a net loss of $14.50 billion, a significant increase from a net loss of $119.55 million in the previous year, primarily due to non-cash asset impairments and other expenses totaling approximately $17.63 billion [3]. - The company experienced a decline of approximately 168,000 net pay-TV subscribers in Q4 2025, compared to a decline of about 253,000 in the same quarter of the previous year [3]. Company Overview - EchoStar Corporation is described as a fully integrated global communications and content delivery leader, providing a range of services including technology, spectrum, engineering, manufacturing, networking services, television entertainment, and connectivity [4].

Core Insights - Health Catalyst (HCAT) reported revenue of $74.68 million for the quarter ended December 2025, reflecting a year-over-year decline of 6.2% while EPS increased to $0.08 from $0.04 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $73.61 million, resulting in a surprise of +1.45%, although the EPS fell short of the consensus estimate of $0.09 by -14.26% [1] Revenue Breakdown - Professional services revenue was $22.81 million, slightly below the estimated $22.88 million, marking an 18.6% decline compared to the same quarter last year [4] - Technology revenue reached $51.87 million, surpassing the estimated $50.74 million, with a modest year-over-year increase of 0.5% [4] Profit Metrics - Adjusted Gross Profit for Professional Services was $4.61 million, slightly below the average estimate of $4.68 million [4] - Adjusted Gross Profit for Technology was $35.35 million, exceeding the estimated $34.51 million [4] Stock Performance - Over the past month, shares of Health Catalyst have returned -6.5%, compared to a -2.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]

Core Insights - Health Catalyst (HCAT) is expected to report quarterly earnings of $0.10 per share, marking a 150% increase year-over-year, while revenues are forecasted at $73.61 million, reflecting a 7.5% decrease compared to the previous year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, indicating analysts' reassessment of their projections [1] Revenue Estimates - The consensus estimate for 'Revenue- Professional services' is $22.88 million, indicating an 18.3% decline from the same quarter last year [4] - Analysts project 'Revenue- Technology' to be $50.74 million, suggesting a year-over-year decrease of 1.7% [4] Profit Estimates - The estimated 'Adjusted Gross Profit- Professional Services' is projected to reach $4.22 million, an increase from $3.78 million in the same quarter last year [4] - For 'Adjusted Gross Profit- Technology', the estimate stands at $34.30 million, compared to $33.35 million reported in the same quarter last year [5] Stock Performance - Over the past month, shares of Health Catalyst have declined by 9.3%, while the Zacks S&P 500 composite has decreased by 2.7% [5] - Health Catalyst currently holds a Zacks Rank 2 (Buy), indicating potential outperformance in the near future [5]

Core Insights - Accenture plc (NYSE:ACN) is a global professional services company specializing in strategy, consulting, digital, technology, and operations, known for strong client relationships and high switching costs, providing a competitive edge [1] - An analyst from Piper Sandler set a price target of $282 for Accenture, indicating a potential price increase of approximately 34.29% from its current price of $210, but the company has a 'Hold' rating due to modest fiscal year 2026 revenue growth guidance of 2% to 5% [2][6] - Accenture's consulting revenue is under pressure, but the company retains a competitive advantage due to its large scale and deep client relationships, helping it remain resilient in a challenging market [3][6] - The adoption of AI presents both opportunities and challenges for Accenture, as it could increase demand for services while also potentially reducing billable hours in certain segments [4] - Accenture's stock is currently priced at $210, with a market capitalization of approximately $130.23 billion, reflecting volatility with a high of $347.10 and a low of $188.73 over the past year [5]

Core Viewpoint - Established technology companies can generate sufficient cash flow to invest in growth and pay dividends, distinguishing them from typical high-growth tech stocks that focus on buybacks and expansion [1]. Group 1: Company Overview - Accenture Plc (ACN) is a global professional services company that provides consulting, technology, and outsourcing solutions, assisting businesses and governments in improving operations and leading technology upgrades [7]. - The company is expanding its role into large-scale AI infrastructure, having been selected to help build sovereign AI data centers across Europe, the Middle East, and Africa (EMEA) [8]. Group 2: Stock Performance - Accenture's stock is currently trading around $201, showing weakness in both short-term and long-term performance, and is near its five-year low at $199.10 [9]. - Recent declines in share price are attributed to slowed client spending on consulting projects, and management has issued a more cautious growth outlook despite ongoing investments in AI [10]. Group 3: Investment Criteria - The stock screening process focused on companies with a market cap of $10 billion or higher, emphasizing established businesses with proven models and durable competitive positions [6]. - A higher number of analysts (12 or more) covering the stock suggests a stronger rating consensus, with Accenture currently rated as a Moderate to Strong Buy [6].

Core Insights - The company's business-to-business division is experiencing increased revenue due to a growing number of corporate travel customers, airlines, and banks utilizing Expedia for technology, inventory, and tools to enhance their operations [1] Group 1 - The business-to-business division is a significant revenue driver for the company [1] - Corporate travel customers are increasingly turning to Expedia for support [1] - Airlines and banks are leveraging Expedia's technology and inventory [1]

Core Insights - The SGA Emerging Markets Growth Strategy experienced a divergence from the market in Q4 2025, with the portfolio returning 0.8% (Gross) and 0.6% (Net), compared to the MSCI EM Net TR Index return of 4.7% and the MSCI EM Growth Net TR Index return of 3.3% [1] - For the full year 2025, the portfolio achieved returns of 23.8% (Gross) and 22.8% (Net), lagging behind the indexes which returned 33.6% and 34.3% respectively [1] - The portfolio anticipates annual revenue growth of 13% and earnings growth of 16% over the next three years [1] Company Focus: Infosys Limited - Infosys Limited (NYSE:INFY) was highlighted as a top contributor in Q4 2025, benefiting from steady execution, resilient recurring revenues, and strong performance in large-scale digital transformation projects [2][3] - As of February 11, 2026, Infosys's stock closed at $15.76 per share, with a one-month return of -16.26% and a twelve-month decline of 27.51% [2] - The company has a market capitalization of $63.76 billion [2] - Despite recent investor sentiment cooling towards India due to softening domestic demand and tariff uncertainties, Infosys's strong operating margins and client retention support robust free cash flow generation [3] - Concerns regarding potential disruptions from AI in outsourced IT services have affected Infosys shares, but the company is well-positioned to assist enterprises with AI deployment challenges [3] - The position in Infosys was trimmed to a below-average weight due to valuation considerations [3]

Group 1: Company Overview - SLB N.V. (NYSE:SLB) is a global oilfield services company headquartered in Houston, Texas, with operations in over 100 countries, providing technology, information solutions, and integrated project management services to optimize reservoir performance [4]. Group 2: Recent Contracts and Developments - SLB N.V. has secured a $1.5 billion contract from Kuwait Oil Company to develop the Mutriba field over five years, which includes responsibilities for design, development, and production management [1]. - In December, SLB N.V. also obtained a five-year contract to provide services to Saudi Arabian Oil Company for its unconventional gas fields, indicating a trend of increased exploration and drilling activity in the region [2]. Group 3: Analyst Ratings and Price Targets - Jefferies raised its price target on SLB N.V. from $51 to $58 while maintaining a Buy rating, citing that the company's valuation is "not challenging" [3]. - UBS also increased its price target on SLB N.V. from $50 to $61, reaffirming a Buy rating on the stock [3].